Double Diff Matrix technology provides routine identification and quantification of the three immature lines involved in leucopoiesis - granulocytic, lymphocytic, and monocytic
The Double Diff Matrix, an exclusive technology incorporated in Horiba ABX Pentra 120 analysers, has already created a great stir in haematology circles, says the company.
The Double Diff Matrix significantly reduces manual differentials, enabling scientists for the first time to distinguish three key cell lines involved in leucopoiesis.
EuroMedlab saw the launch of the Pentra DF 120, designed to make Double Diff Matrix technology accessible to all laboratories looking for a robust routine platform.
Combining flow cytometry and cytochemistry, Double Diff Matrix technology provides routine identification and quantification of the three immature lines involved in leucopoiesis - granulocytic, lymphocytic, and monocytic.
Because it offers true reflex testing, the number of slide re-examinations is reduced and the haematologist receives a fast report enabling rapid decision making.
The ABX Pentra DF 120's overall performance is also impressive, says Horiba ABX: 32 parameters, 120 samples per hour, and an expert validation station provides automatic confirmation and validation of results.
With the addition of the optional SPS Evolution integrated slide-maker, a throughput of 120 samples per hour can easily be achieved.
The SPS Evolution also enables safe and efficient automation and standardisation of blood smear testing.
Slide handling is eliminated, while the system also offers a wide selection of staining protocols, barcode reading and on-slide patient data printing.
While useable as a stand-alone routine instrument, the ABX Pentra 120 DF can be connected to other Horiba ABX analysers through the Pentra ML multilink system also launched at EuroMedlab.
Furthermore, the powerful feature-rich software simplifies workflow allocation, data management, automatic or manual validation of results and other tasks.
